Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ad4-Env150KN
- Development stage
- Phase 1
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intranasal
01
Overview
Ad4-Env150KN is an experimental HIV vaccine that uses a replication-competent adenovirus serotype 4 (Ad4) vector to deliver HIV envelope proteins. It is administered intranasally as a liquid spray and is designed to elicit immune responses against HIV. The vaccine contains a live adenovirus that has been genetically modified to produce pieces of protein from the HIV virus. As the virus reproduces, it may cause an immune response to both adenovirus and to HIV proteins. This experimental vaccine is being studied as part of a prime-boost vaccination strategy for HIV prevention.
02
Targets
CD46 (CD46 Molecule)Env (HIV-1 envelope glycoprotein)
Beyond the preview
Go deeper on Ad4-Env150KN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ad4-Env150KN.